Effectiveness, safety, and biomarker analysis of lenvatinib plus toripalimab as chemo-free therapy in advanced intrahepatic cholangiocarcinoma: a real-world study
Lenvatinib plus toripalimab represents an effective and well-tolerated chemo-free therapeutic option for advanced ICC. Baseline CA19-9 levels and IDH1 mutations may serve as predictive treatment-related biomarkers.
Authors
- Jiashuo Chao (ORCID: https://orcid.org/0000-0002-6578-5967)
- Shuofeng Li (ORCID: https://orcid.org/0000-0002-6033-6476)
- Chengpei Zhu (ORCID: https://orcid.org/0000-0002-0291-782X)
- Xinting Sang (ORCID: https://orcid.org/0000-0003-1952-0527)
- Ziyu Xun
- Weidong Duan
- Haitao Zhao (ORCID: https://orcid.org/0000-0002-3444-8044)
- Kai Liu (ORCID: https://orcid.org/0000-0002-7584-9231)
- Hao Wang (ORCID: https://orcid.org/0000-0002-3511-3895)
- Xu Yang (ORCID: https://orcid.org/0000-0002-5752-7255)
- Yunchao Wang (ORCID: https://orcid.org/0000-0002-3702-3826)
- Mingjian Piao (ORCID: https://orcid.org/0009-0005-4981-5942)
- Xiaobo Yang (ORCID: https://orcid.org/0000-0001-6164-4131)
- Shanshan Wang (ORCID: https://orcid.org/0000-0001-6214-1405)
- Nan Zhang (ORCID: https://orcid.org/0009-0006-0411-738X)
Institutions
- Capital Medical University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking Union Medical College Hospital (CN)
- Beijing YouAn Hospital (CN)
- Beijing Haidian Hospital (CN)
- Shandong First Medical University (CN)
Publication Details
- Journal
- Cancer Immunology Immunotherapy
- Published
- 2024-10-03
- DOI
- https://doi.org/10.1007/s00262-024-03841-z
- Citations
- 5
- Primary Topic
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.86
Funders
- Peking Union Medical College Hospital
- Chinese Society of Clinical Oncology
- National Ten Thousand Talent Program